Literature DB >> 8198931

The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.

K Chiba1, A Saitoh, E Koyama, M Tani, M Hayashi, T Ishizaki.   

Abstract

1. The metabolism of imipramine (N-demethylation and 2-hydroxylation) was studied in relation to the activity of S-mephenytoin 4'-hydroxylase in human liver microsomes. 2. Eadie-Hofstee plots for the formation of despiramine and 2-hydroxyimipramine were biphasic, suggesting that at least two enzymes are involved in both the N-demethylation and 2-hydroxylation of imipramine by human liver microsomes. 3. The respective mean (+/- s.d.) kinetic parameters for the N-demethylation and 2-hydroxylation of imipramine derived from a two-enzyme kinetic analysis were: Km1 = 1.1 +/- 0.4 and 1.6 +/- 0.6 microM, Vmax1 = 0.11 +/- 0.03 and 0.15 +/- 0.07 nmol mg-1 min-1, and Vmax1/Km1 = 0.10 +/- 0.02 and 0.09 +/- 0.04 ml mg-1 min-1; Km2 = 214 +/- 84 and 257 +/- 148 microM, Vmax2 = 2.22 +/- 0.69 and 0.53 +/- 0.15 nmol mg-1 min-1, and Vmax2/Km2 = 0.011 +/- 0.001 and 0.003 +/- 0.002 ml mg-1 min-1. 4. With regard to imipramine N-demethylation and 2-hydroxylation at 2 microM (representing high-affinity reactions) and at 400 microM (representing low-affinity reactions), only N-demethylation at 2 microM showed a close correlation with the 4'-hydroxylation of S-mephenytoin (rs = 0.952, P < 0.01; n = 10 livers). 5. Concentrations up to 250 microM S-mephenytoin inhibited the N-demethylation of imipramine (2 microM), but no further inhibition was observed using concentrations from 250 to 750 microM. 6. Imipramine inhibited S-mephenytoin 4'-hydroxylation competitively with a Ki value of 12.5 microM.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198931      PMCID: PMC1364753          DOI: 10.1111/j.1365-2125.1994.tb04269.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  Inhibitors of imipramine metabolism by human liver microsomes.

Authors:  E Skjelbo; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

2.  Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.

Authors:  D R Sohn; K Kobayashi; K Chiba; K H Lee; S G Shin; T Ishizaki
Journal:  J Pharmacol Exp Ther       Date:  1992-09       Impact factor: 4.030

3.  Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

Authors:  T Andersson; C G Regårdh; M L Dahl-Puustinen; L Bertilsson
Journal:  Ther Drug Monit       Date:  1990-07       Impact factor: 3.681

4.  First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.

Authors:  K Brøsen; L F Gram
Journal:  Clin Pharmacol Ther       Date:  1988-04       Impact factor: 6.875

5.  Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2.

Authors:  T Yasumori; N Murayama; Y Yamazoe; R Kato
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

Review 6.  Clinical pharmacokinetics of imipramine and desipramine.

Authors:  F R Sallee; B G Pollock
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

7.  Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Clin Pharmacol Ther       Date:  1986-11       Impact factor: 6.875

8.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

Authors:  K Brøsen; R Klysner; L F Gram; S V Otton; P Bech; L Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

Authors:  L Bertilsson; T K Henthorn; E Sanz; G Tybring; J Säwe; T Villén
Journal:  Clin Pharmacol Ther       Date:  1989-04       Impact factor: 6.875

10.  Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics.

Authors:  K Brøsen; L F Gram; R Klysner; P Bech
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more
  7 in total

Review 1.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

2.  The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes.

Authors:  K Kobayashi; T Yamamoto; K Chiba; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

3.  Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.

Authors:  J K Coller; A A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

4.  Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.

Authors:  K Yoshimoto; H Echizen; K Chiba; M Tani; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

5.  Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.

Authors:  H Madsen; K K Nielsen; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Few alterations in clinical pathology and histopathology observed in a CYP2C18&19 humanized mice model.

Authors:  Susanne Löfgren; Stina Ekman; Ylva Terelius; Ronny Fransson-Steen
Journal:  Acta Vet Scand       Date:  2008-11-27       Impact factor: 1.695

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.